指南与共识中药与中成药合理使用

中国中成药临床实践指南的方法学、证据与质量批判性综述

Clinical practice guidelines of Chinese patent medicine in China: A critical review.
指南 / 共识 · Complement Ther Med · 2024-08-23

该研究检索2019至2022年发布的中成药临床应用指南,由两名评价者独立筛选与提取资料,共分析29部指南、262条推荐和2308篇参考文献。指南方法学遵循证据为核心、共识为补充、经验为参考及WHO手册,但74.5%证据为低或极低质量,83.6%推荐为弱推荐。

要点

  • 中成药指南推荐多基于低质量证据,弱推荐占83.6%。
  • AGREE II中严谨性53.97%、应用性仅5.11%,为薄弱领域。
  • 多数指南实施质量高或中等,但证据质量限制推荐可信度。

核心结论

  • 中成药指南在方法学、质量和实施方面表现令人印象深刻,但推荐可信度因证据质量低而被降级。

研究设计与样本

  • 检索2019至2022年发表的中成药临床应用指南,由两名评价者独立筛选和数据提取。
  • 共纳入29部指南,提取262条推荐和2308篇参考文献,并统计分析基本信息、证据和推荐。
  • 使用实施评价工具和AGREE II评估指南质量和实施情况。

主要发现

  • 所有中成药指南遵循证据为核心、共识为补充、经验为参考的原则及WHO手册提供的方法。
  • 每部指南平均引用89篇参考文献,每条推荐平均引用8篇。
  • 随机对照试验和系统评价分别占所有参考文献的89%和0.9%。
  • 74.5%的证据为低或极低质量,83.6%的推荐为弱推荐。
  • 13.7%的推荐基于专家共识,9.5%的强推荐基于低或极低质量证据。

关键数值与推荐

  • AGREE II各领域得分:范围和目的79.63%,编辑独立性79.27%,清晰性72.59%,利益相关者参与69.99%,严谨性53.97%,应用性5.11%。
  • 大多数指南的实施质量被评为高(44.8%)或中等(55.2%)。

临床怎么用

  • 临床参考中成药指南推荐时,需注意多数推荐为弱推荐且基于低或极低质量证据。
  • 应用指南时应结合证据质量谨慎决策,尤其关注严谨性和应用性得分较低的领域。

局限性

  • 推荐可信度受低质量证据限制而降级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyze the methodology, evidence, recommendations, quality, and implementation of traditional Chinese patent medicine (CPM) guidelines. METHODS: We retrieved clinical application guidelines of CPM published from 2019 to 2022. Independent screening and data extraction were performed by two evaluators. The basic information about the guidelines, including evidence and recommendations, were extracted and statistically analyzed. Quality and implementation were evaluated using the Implementation Evaluation Tool and Appraisal of Guidelines for Research & Evaluation (AGREE) II. RESULTS: In total, 29 guidelines were analyzed, including 262 recommendations and 2308 references. All the CPM guidelines followed the principle of "evidence as a core, consensus as a supplement, and experience as a reference" and the methods provided by WHO Handbook. An average of 89 references were cited in each guideline and 8 in each recommendation. Randomized controlled trials and systematic reviews constituted 89 % and 0.9 %, respectively, of all references. Low or very low-quality evidence characterized 74.5 % and weak recommendations characterized 83.6 %. Of all recommendations, 13.7 % were based on expert consensus, and 9.5 % of strong recommendations were based on low or very low-quality evidence. The AGREE II scores for each domain were: scope and purpose (79.63 %) and editorial independence (79.27 %), followed by clarity of presentation (72.59 %), stakeholder involvement (69.99 %), rigor of development (53.97 %) and applicability (5.11 %). The implementation quality of most guidelines was either high (44.8 %) or moderate (55.2 %). CONCLUSIONS: The results for CPM guidelines were impressive in terms of methodology, quality, and implementation. However, confidence in CPM recommendations was downgraded by low quality of evidence.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Wang JX, Sun R, Si DX, et al. Clinical practice guidelines of Chinese patent medicine in China: A critical review. Complement Ther Med. 2024. PMID: 39181170. doi:10.1016/j.ctim.2024.103077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。